We are live on ! Find out more
VCIM

Velan Capital Investment Management Portfolio holdings

AUM $160M
1-Year Est. Return 517.12%
This Fund
S&P 500
This Quarter Est. Return
+15.2%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$101M
AUM Growth
+$4.03M
Cap. Flow
-$1.4M
Cap. Flow %
-1.38%
Top 10 Hldgs %
69.32%
Holding
57
New
10
Increased
16
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$7.65M
2
ARVN icon
Arvinas
ARVN
+$3.68M
3
CDTX
Cidara Therapeutics
CDTX
+$2.4M
4
STRO icon
Sutro Biopharma
STRO
+$1.66M
5
TARA icon
Protara Therapeutics
TARA
+$1.63M

Top Sells

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$8.32M
2
SWTX
SpringWorks Therapeutics
SWTX
+$8.19M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$1.36M
4
TIL icon
Instil Bio
TIL
+$1.2M
5
IMNM icon
Immunome
IMNM
+$1.03M

Sector Composition

Rank Sector Weight
1 Healthcare 98.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELEV
51
DELISTED
Elevation Oncology
ELEV
– –
-45,000
Closed -$11.7K
IMNM icon
52
Immunome
IMNM
$3.17B
– –
-153,500
Closed -$1.03M
KRON
53
DELISTED
Kronos Bio
KRON
– –
-35,000
Closed -$28.9K
RGLS
54
DELISTED
Regulus Therapeutics
RGLS
– –
-80,000
Closed -$140K
SLRN
55
DELISTED
ACELYRIN
SLRN
– –
-3,366,945
Closed -$8.32M
SWTX
56
DELISTED
SpringWorks Therapeutics
SWTX
– –
-185,520
Closed -$8.19M
TIL icon
57
Instil Bio
TIL
$50.7M
– –
-69,000
Closed -$1.2M
1 2
3

Similar funds

BFAG
Blackston Financial Advisory Group The Villages, Florida $160M AUM 16.38% 1-Year Est. Return
SLG
Sanchez Levi Garrett $159M AUM
SMF
Sterling Manor Financial Saratoga Springs, New York $160M AUM 13.84% 1-Year Est. Return
LCA
Legend Capital Advisors New York $160M AUM
SGCM
Sanchez Gaunt Capital Management Reno, Nevada $160M AUM
RP
RIHO Partners Tucson, Arizona $159M AUM
PCC
Perry Creek Capital New York $160M AUM 3.05% 1-Year Est. Return
RCWM
Royal Capital Wealth Management Carmel, Indiana $161M AUM 18.42% 1-Year Est. Return

Velan Capital Investment Management's Q2 2025 Portfolio in Review

As of Q2 2025, Velan Capital Investment Management held 57 positions worth $101M, up 4.1% from $97.2M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Velan Capital Investment Management's Q2 2025 filing shows 10 new, 16 increased, 5 reduced and 7 closed positions. Its largest new stake was Alumis Inc: 1,620,846 shares worth $4.86M. The largest sale was ACELYRIN, an estimated $8.32M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

  • Velan Capital Investment Management's largest Q2 2025 buy was Alumis Inc: 1,620,846 shares worth $4.86M.
  • Velan Capital Investment Management added most to Sutro Biopharma in Q2 2025, an estimated $1.66M increase.
  • Velan Capital Investment Management's biggest Q2 2025 reduction was Praxis Precision Medicines, cutting an estimated $1.36M.
  • Velan Capital Investment Management fully exited ACELYRIN in Q2 2025, selling an estimated $8.32M.
  • Velan Capital Investment Management's ten largest holdings make up 69% of its $101M portfolio in Q2 2025.
  • Velan Capital Investment Management opened 10 new positions and closed 7 in Q2 2025.
  • Velan Capital Investment Management's portfolio value rose 4.1% quarter-over-quarter to $101M.

Based on Velan Capital Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.